Compare NWN & LKFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | LKFT |
|---|---|---|
| Founded | 1859 | N/A |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2018 | 2015 |
| Metric | NWN | LKFT |
|---|---|---|
| Price | $50.75 | $29.07 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $54.33 | N/A |
| AVG Volume (30 Days) | ★ 273.7K | 134.6K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ 36.45 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $1,289,363,000.00 | N/A |
| Revenue This Year | $11.37 | N/A |
| Revenue Next Year | $4.46 | N/A |
| P/E Ratio | $21.87 | ★ N/A |
| Revenue Growth | ★ 11.83 | N/A |
| 52 Week Low | $39.29 | $28.00 |
| 52 Week High | $55.99 | $30.91 |
| Indicator | NWN | LKFT |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 48.04 |
| Support Level | $48.36 | N/A |
| Resistance Level | $51.93 | $30.91 |
| Average True Range (ATR) | 1.14 | 0.55 |
| MACD | 0.16 | -0.12 |
| Stochastic Oscillator | 50.11 | 1.47 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.